Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial

医学 中期分析 内科学 临床终点 危险系数 肿瘤科 化疗 新辅助治疗 围手术期 食管癌 不利影响 随机对照试验 癌症 外科 置信区间 乳腺癌
作者
Yan Zheng,Guanghui Liang,Dongfeng Yuan,Xianben Liu,Yufeng Ba,Zimin Qin,Sining Shen,Zhenxuan Li,Haibo Sun,Baoxing Liu,Quanli Gao,Peng Li,Zongfei Wang,Shilei Liu,Jianping Zhu,Haoran Wang,Haibo Ma,Zhenzhen Liu,Fei Zhao,Jun Zhang
出处
期刊:Cancer communications [Wiley]
被引量:7
标识
DOI:10.1002/cac2.12604
摘要

Abstract Background In the era of immunotherapy, neoadjuvant immunochemotherapy (NAIC) for the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) is used clinically but lacks of high‐level clinical evidence. This study aimed to compare the safety and long‐term efficacy of NAIC followed by minimally invasive esophagectomy (MIE) with those of neoadjuvant chemotherapy (NAC) followed by MIE. Methods A prospective, single‐center, open‐label, randomized phase III clinical trial was conducted at Henan Cancer Hospital, Zhengzhou, China. Patients were randomly assigned to receive either neoadjuvant toripalimab (240 mg) plus paclitaxel (175 mg/m 2 ) + cisplatin (75 mg/m 2 ) (toripalimab group) or paclitaxel + cisplatin alone (chemotherapy group) every 3 weeks for 2 cycles. After surgery, the toripalimab group received toripalimab (240 mg every 3 weeks for up to 6 months). The primary endpoint was event‐free survival (EFS). The pathological complete response (pCR) and overall survival (OS) were key secondary endpoints. Adverse events (AEs) and quality of life were also assessed. Results Between May 15, 2020 and August 13, 2021, 252 ESCC patients ranging from T1N1‐3M0 to T2‐3N0‐3M0 were enrolled for interim analysis, with 127 in the toripalimab group and 125 in the chemotherapy group. The 1‐year EFS rate was 77.9% in the toripalimab group compared to 64.3% in the chemotherapy group (hazard ratio [HR] = 0.62; 95% confidence interval [CI] = 0.39 to 1.00; P = 0.05). The 1‐year OS rates were 94.1% and 83.0% in the toripalimab and chemotherapy groups, respectively (HR = 0.48; 95% CI = 0.24 to 0.97; P = 0.037). The patients in the toripalimab group had a higher pCR rate (18.6% vs. 4.6%; P = 0.001). The rates of postoperative Clavien‐Dindo grade IIIb or higher morbidity were 9.8% in the toripalimab group and 6.8% in the chemotherapy group, with no significant difference observed ( P = 0.460). The rates of grade 3 or 4 treatment‐related AEs did not differ between the two groups (12.5% versus 12.4%). Conclusions The interim results of this ongoing trial showed that in resectable ESCC, the addition of perioperative toripalimab to NAC is safe, may improve OS and might change the standard treatment in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
只想顺利毕业的科研狗完成签到,获得积分10
1秒前
普鲁卡因发布了新的文献求助10
2秒前
Helios完成签到,获得积分10
3秒前
xueshidaheng完成签到,获得积分0
3秒前
BK_201完成签到,获得积分10
3秒前
风信子完成签到,获得积分10
4秒前
abiorz完成签到,获得积分0
4秒前
窗外是蔚蓝色完成签到,获得积分0
5秒前
nanostu完成签到,获得积分10
7秒前
吐司炸弹完成签到,获得积分10
7秒前
mayfly完成签到,获得积分10
8秒前
Brief完成签到,获得积分10
8秒前
大模型应助科研通管家采纳,获得10
9秒前
小二郎应助科研通管家采纳,获得10
9秒前
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
Amikacin完成签到,获得积分10
9秒前
鹏举瞰冷雨完成签到,获得积分10
9秒前
整齐的惮完成签到 ,获得积分10
10秒前
1122完成签到 ,获得积分10
10秒前
情怀应助Cheung2121采纳,获得30
12秒前
完犊子完成签到,获得积分20
12秒前
神秘玩家完成签到 ,获得积分10
13秒前
heher完成签到 ,获得积分10
17秒前
那些兔儿完成签到 ,获得积分0
20秒前
量子星尘发布了新的文献求助10
21秒前
24秒前
昵称666发布了新的文献求助20
26秒前
31秒前
韭菜盒子发布了新的文献求助10
31秒前
落叶听风笑完成签到,获得积分10
32秒前
西扬完成签到 ,获得积分10
32秒前
Pises完成签到,获得积分10
38秒前
今后应助韭菜盒子采纳,获得10
39秒前
40秒前
大勺完成签到 ,获得积分10
41秒前
科研狗敏敏完成签到,获得积分20
42秒前
牛马完成签到 ,获得积分10
42秒前
45秒前
普鲁卡因完成签到,获得积分10
46秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022